Caristo's Technology to be Featured in Non-Contrast CT and Late-Breaking Stroke Prediction Data at ESC 2026

Investigator-led abstracts will explore new data on FAI-Score's prognostic value, alongside emerging applications in stroke prediction and virtual biopsy of arterial inflammation

OXFORD, England and STAMFORD, Conn., Aug. 24, 2026 /PRNewswire/ -- Caristo Diagnostics, a global leader in AI technologies for cardiovascular disease, today announced that new University of Oxford-led research using Caristo's technologies will be presented at the European Society of Cardiology (ESC) Congress, taking place in Munich, Germany, from August 28-31, 2026. The presentations will highlight the scientific breadth of Caristo's AI platform—including emerging applications in non-contrast cardiac CT for inflammation, stroke prediction, and virtual biopsy of arterial inflammation—which are distinct from and build on the company's commercially available portfolio for coronary inflammation and AI plaque analysis.

Cardiovascular diseases (CVDs) are the leading cause of death globally, with 85% of these deaths attributed to heart attacks and strokes.¹ Localized inflammation is increasingly recognized as a key biological driver of these events, creating new opportunities to identify patients earlier through routine imaging. At ESC, late-breaking data to be presented by Charalambos Antoniades, British Heart Foundation Chair of Cardiovascular Medicine at the University of Oxford, will examine the potential application of Caristo's AI to predict stroke from routine cardiac CT scans. Additional abstracts will explore emerging uses of Caristo's patented FAI-Score™, including the assessment of inflammatory signals on non-contrast cardiac CT scans.

"Cardiovascular inflammation is at the core of cardiovascular disease biology," said Steve Deitsch, CEO of Caristo Diagnostics. "With CaRi-Heart now FDA-authorized and in clinical use in the U.S., the research to be presented at ESC will explore the broader potential of our platform, including early-stage data applying FAI-Score to non-contrast cardiac CT that we're continuing to develop. New stroke prediction research will also be presented, examining the potential of our technology to help address cardiovascular diseases beyond the coronary artery disease in the future."

Details for the ESC presentations featuring research that uses Caristo's technologies are as follows:

Using AI to Detect Atrial Myopathy and Predict Cardioembolic Stroke from Routine Cardiac CT: The ORFAN-MAESTRIA study

• Session: Late-Breaking Clinical Science: Advanced Cardiovascular Imaging
• Presenter: Prof. Charalambos Antoniades
• Date: Monday, August 31
• Time: 2:15-3:15 p.m. CEST
• Location: Prishtina (Hall A3)

Coronary Inflammation Quantified On Contrast and Non-Contrast Cardiac CT Identifies High-Risk Individuals Independently from Coronary Calcification: Implications For Those With Zero Calcium Score

• Session: From Pixels to Prognosis: Imaging, Artificial Intelligence, and the Future of Coronary Artery Disease Diagnosis
• Presenter: Prof. Kenneth Chan
• Date: Monday, August 31
• Time: 10:45-11:45 a.m. CEST
• Location:  Science Box 3 (Research Gateway-Hall A1)

Coronary Inflammation Predicts Cardiovascular Risk in the Absence of Standard Modifiable Risk Factors (SMuRFs): The ORFAN Study

• Session: Predicting Cardio-Renal-Metabolic Disease
• Presenter: Prof. Leanne Eveson
• Date: Sunday, August 30
• Time: 10:15-11:00 a.m. CEST
• Location: Station 7 (Research Gateway-Hall A1)

"Virtual Biopsy" of Arterial Cytokine Activation Predicts Long-Term Cardiac Mortality in Over 80,000 Patients from UK and USA

• Session: Prevention Scores: Risk Prediction and Polygenic Risk
• Presenter: Prof. Christos Kotanidis
• Date: Saturday, August 29
• Time: 3:45-4:45 p.m. CEST
• Location: Science Box 2 (Research Gateway-Hall A1)

In addition, University of Oxford experts will present at these specialized sessions discussing the growing role of AI in cardiovascular disease management and risk stratification:

Great Debates: Coronary Computed Tomography for Cardiovascular Disease Prevention in the Era Of Artificial Intelligence

• Presenter: Prof. Charalambos Antoniades
• Date: Friday, August 28
• Time: 8:15-9:45 a.m. CEST
• Location: Beirut (Hall A3)

Clinical Case Management: Using Artificial Intelligence to Guide Treatments in Practice - Co-Pilot for Risk Stratification

• Co-Chair: Prof. Keith Channon
• Date: Sunday, August 30
• Time: 1:45-3:00 p.m. CEST
• Location: Digital Health Stage (Hall B3)

The ESC research presentations will preview future potential applications and are distinct from Caristo's currently available clinical portfolio:

• CaRi-Heart® has received U.S. Food and Drug Administration (FDA) De Novo marketing authorization and is the first and only technology authorized in the U.S. to quantify coronary inflammation from routine coronary CT angiography (CCTA). It is also commercially available in Europe, the UK, Switzerland, and Australia.
• CaRi-Plaque® has received U.S. FDA clearance for AI-assisted coronary plaque and stenosis analysis, complementing CaRi-Heart by evaluating quantitative plaque.

About Caristo Diagnostics
Caristo Diagnostics is a global leader in AI technologies for cardiovascular disease, founded as a spin-out from the University of Oxford. Its award-winning CaRi-Heart® technology helps detect hidden heart disease and identify people at risk of heart attack before symptoms appear. Working with leading hospitals, research institutions, and pharmaceutical partners, Caristo aims to save lives through early detection and personalized prevention. The company was named a 2026 Technology Pioneer by the World Economic Forum in June 2026. Learn more at www.caristo.com and follow Caristo on LinkedIn, YouTube, and X.

Media Contact:
Supreme Communications for Caristo
[email protected] 

SOURCE Caristo Diagnostics